title: EGFR-mutated lung cancer with T790M-acquired resistance in the brain and histologic transformation in the lung.
abstract: This case report describes the rare occurrence of a T790M resistance mutation found in a central nervous system (CNS) parenchymal metastasis. A concomitant squamous histology transformation in a lung non-T790M-resistant metastasis is also described. The authors hypothesize that this CNS resistance and histology transformation may have resulted from intermittent use of erlotinib treatment. This case report emphasizes the complexities of using erlotinib in the induction setting.
authors.affiliation: From aCity of Hope Comprehensive Cancer Center, Duarte, California; bDavid Geffen School of Medicine at UCLA, Los Angeles, California; and cCedars Sinai Medical Center, Hollywood, California.
authors.forename: Kevin S
authors.initials: KS
authors.lastname: Scher
authors.forename: Juan-Sebastian
authors.initials: JS
authors.lastname: Saldivar
authors.forename: Michael
authors.initials: M
authors.lastname: Fishbein
authors.forename: Alberto
authors.initials: A
authors.lastname: Marchevsky
authors.forename: Karen L
authors.initials: KL
authors.lastname: Reckamp
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D001932:Brain Neoplasms / Q000175:diagnosis / Q000188:drug therapy / Q000235:genetics* / Q000556:secondary*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy / Q000235:genetics* / Q000473:pathology*; D002294:Carcinoma, Squamous Cell / Q000175:diagnosis / Q000209:etiology*; D002471:Cell Transformation, Neoplastic / Q000187:drug effects / Q000235:genetics; D066246:ErbB Receptors / Q000037:antagonists & inhibitors / Q000235:genetics*; D000069347:Erlotinib Hydrochloride; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy / Q000235:genetics* / Q000473:pathology*; D008875:Middle Aged; D016609:Neoplasms, Second Primary / Q000175:diagnosis / Q000209:etiology*; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D011799:Quinazolines / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D000069347:Erlotinib Hydrochloride; D066246:ErbB Receptors